BR112012018947B8 - anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica - Google Patents
anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica Download PDFInfo
- Publication number
- BR112012018947B8 BR112012018947B8 BR112012018947A BR112012018947A BR112012018947B8 BR 112012018947 B8 BR112012018947 B8 BR 112012018947B8 BR 112012018947 A BR112012018947 A BR 112012018947A BR 112012018947 A BR112012018947 A BR 112012018947A BR 112012018947 B8 BR112012018947 B8 BR 112012018947B8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- pharmaceutical composition
- pharmaceutical
- caprin
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica de acordo com a presente invenção, foi identificada uma proteína antígeno do câncer que é especificamente expressa sobre as superfícies de células cancerosas e, portanto, é fornecido o uso de um anticorpo direcionado contra a proteína antígeno do câncer como um agente para o tratamento e/ou prevenção de um câncer. especificamente, a presente invenção fornece uma composição farmacêutica para o tratamento e/ou prevenção de um câncer, que compreende um anticorpo ou fragmento do mesmo como um ingrediente ativo possuindo reatividade imunológica a um polipeptídeo parcial da caprin-1, que é representada por qualquer uma das sequências pares numeradas como seq id nos: 2 a 30, em que o polipeptídeo tem a sequência de aminoácidos representada pela seq id no: 37 ou uma sequência de aminoácidos possuindo 80% ou mais de identidade de sequência com a sequência de aminoácidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010023451 | 2010-02-04 | ||
| PCT/JP2011/052403 WO2011096528A1 (ja) | 2010-02-04 | 2011-02-04 | 癌の治療及び／又は予防用医薬組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BR112012018947A2 BR112012018947A2 (pt) | 2017-06-27 |
| BR112012018947A8 BR112012018947A8 (pt) | 2017-12-19 |
| BR112012018947B1 BR112012018947B1 (pt) | 2020-04-28 |
| BR112012018947B8 true BR112012018947B8 (pt) | 2020-06-02 |
Family
ID=44355522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012018947A BR112012018947B8 (pt) | 2010-02-04 | 2011-02-04 | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9115200B2 (pt) |
| EP (1) | EP2532365B1 (pt) |
| JP (1) | JP5742714B2 (pt) |
| KR (1) | KR101842893B1 (pt) |
| CN (1) | CN102821788B (pt) |
| BR (1) | BR112012018947B8 (pt) |
| CA (1) | CA2788715C (pt) |
| DK (1) | DK2532365T3 (pt) |
| ES (1) | ES2583627T3 (pt) |
| HU (1) | HUE030103T2 (pt) |
| MX (1) | MX340014B (pt) |
| PL (1) | PL2532365T3 (pt) |
| PT (1) | PT2532365T (pt) |
| RU (1) | RU2607366C2 (pt) |
| WO (1) | WO2011096528A1 (pt) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2498819C2 (ru) | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| DK2733492T3 (en) | 2008-08-05 | 2016-04-25 | Toray Industries | Method for detection of cancer |
| HUE030742T2 (en) | 2010-02-04 | 2017-06-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| RU2624029C2 (ru) * | 2010-02-04 | 2017-06-30 | Торэй Индастриз, Инк. | Лекарственный препарат для лечения и/или профилактики рака |
| DK2532364T3 (en) | 2010-02-04 | 2016-08-15 | Toray Industries | PHARMACEUTICAL COMPOSITION CONTAINING ANTI CAPRIN-1 ANTIBODIES FOR TREATMENT AND / OR PREVENTION OF CANCER |
| DK2532365T3 (en) | 2010-02-04 | 2016-08-15 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER |
| BR112012018949A2 (pt) | 2010-02-04 | 2020-09-01 | Toray Industries | Composições farmacêuticas, anticorpos, combinação farmacêutica, métodos para o tratamento e/ou prevenção de um câncer, usos de uma composição farmacêutica, uso5 de um anticorpo e uso de uma combinação farmacêutica |
| RU2567657C2 (ru) | 2010-02-04 | 2015-11-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| BR112014002616B1 (pt) | 2011-08-04 | 2022-01-18 | Toray Industries, Inc | Método para detectar câncer pancreático |
| KR101980554B1 (ko) | 2011-08-04 | 2019-05-21 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| ES2618026T3 (es) | 2011-08-04 | 2017-06-20 | Toray Industries, Inc. | Composición farmacológica para el tratamiento y/o la prevención del cáncer |
| ES2634249T3 (es) | 2011-08-04 | 2017-09-27 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| ES2609846T3 (es) | 2011-08-04 | 2017-04-24 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o prevención del cáncer pancreático |
| DK2740794T3 (en) | 2011-08-04 | 2018-06-14 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION |
| PT2740793T (pt) | 2011-08-04 | 2018-02-23 | Toray Industries | Composição de fármacos para o tratamento e/ou a prevenção de cancro |
| BR112014021103A2 (pt) * | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| EP2818482B1 (en) * | 2012-02-21 | 2019-05-22 | Toray Industries, Inc. | Pharmaceutical composition for treatment of cancer |
| MX357505B (es) | 2012-02-21 | 2018-07-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| MX363136B (es) | 2012-02-21 | 2019-03-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| CA2869120C (en) * | 2012-03-30 | 2023-05-23 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
| JP6244911B2 (ja) * | 2012-07-19 | 2017-12-13 | 東レ株式会社 | 癌の検出方法 |
| PT2876447T (pt) | 2012-07-19 | 2020-02-03 | Toray Industries | Método para deteção de cancro |
| RU2678138C2 (ru) | 2013-08-09 | 2019-01-23 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| US11492410B2 (en) * | 2016-03-28 | 2022-11-08 | Toray Industries, Inc. | Method for treating cancer by administration of antibodies that bind to extracellular region portion of MCEMP1 protein |
| CN115317603A (zh) | 2016-07-07 | 2022-11-11 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| RU2766586C2 (ru) * | 2016-10-28 | 2022-03-15 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или предупреждения злокачественной опухоли |
| CN111936164B (zh) | 2018-03-30 | 2024-09-17 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| BR112021016056A2 (pt) | 2019-02-15 | 2021-12-14 | Integral Molecular Inc | Anticorpos de claudina 6 e usos dos mesmos |
| WO2020168024A1 (en) * | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
| CN113993549A (zh) | 2019-03-15 | 2022-01-28 | 博尔特生物治疗药物有限公司 | 靶向her2的免疫缀合物 |
| KR20220152309A (ko) | 2020-03-12 | 2022-11-15 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| EP4119156A4 (en) | 2020-03-12 | 2024-05-08 | Toray Industries, Inc. | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| KR20220153615A (ko) | 2020-03-12 | 2022-11-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| US20230159635A1 (en) | 2020-03-12 | 2023-05-25 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| US20230139178A1 (en) | 2020-03-12 | 2023-05-04 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| US11768197B1 (en) * | 2021-06-19 | 2023-09-26 | Eggschain, Inc. | Rapid fertility and health indicator |
| MX2023014500A (es) | 2021-06-23 | 2024-01-25 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| EP4360648A1 (en) | 2021-06-23 | 2024-05-01 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2023008462A1 (pt) | 2021-07-27 | 2023-02-02 | ||
| MX2024001099A (es) | 2021-07-27 | 2024-02-23 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| KR20240042416A (ko) | 2021-07-27 | 2024-04-02 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| JPWO2023033129A1 (pt) | 2021-09-03 | 2023-03-09 | ||
| TW202430574A (zh) | 2022-11-30 | 2024-08-01 | 美商積分分子股份有限公司 | 針對密連蛋白６之抗體，包括其雙特異性格式 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0770628B9 (en) | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
| TR200101541T2 (tr) | 1998-04-03 | 2002-06-21 | Chugai Seiyaku Kabushiki Kaisha | İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor. |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| IL140845A0 (en) | 1998-07-14 | 2002-02-10 | Corixa Corp | Compositions for therapy and diagnosis of prostate cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| AU4185100A (en) | 1999-04-02 | 2000-10-23 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| CH694589A5 (de) * | 1999-06-25 | 2005-04-15 | Genentech Inc | Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern. |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| CA2388822A1 (en) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| CZ20023567A3 (cs) | 2000-03-29 | 2003-11-12 | Corixa Corporation | Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic |
| AU2002239422B2 (en) | 2000-11-30 | 2006-12-07 | E. R. Squibb & Sons, L.L.C. | Transgenic transchromosomal rodents for making human antibodies |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| US20040236091A1 (en) | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| JP4115281B2 (ja) | 2001-05-11 | 2008-07-09 | キリンファーマ株式会社 | ヒト抗体λ軽鎖遺伝子を含むヒト人工染色体、および子孫伝達可能な該ヒト人工染色体を含む非ヒト動物 |
| WO2002092001A2 (en) | 2001-05-11 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP2388265A1 (en) | 2002-02-22 | 2011-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US20050003390A1 (en) * | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| US20060121029A1 (en) | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
| WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| EP1629119A2 (en) | 2003-04-29 | 2006-03-01 | Wyeth | Methods for diagnosing aml and mds by differential gene expression |
| JP2007516693A (ja) | 2003-06-09 | 2007-06-28 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | 癌の治療および診断のための組成物および方法 |
| WO2005007830A2 (en) | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| EP2361929A1 (en) | 2004-01-26 | 2011-08-31 | Debiovision Inc. | Neoplasm-specific polypeptides and their use |
| WO2005090407A1 (en) | 2004-03-19 | 2005-09-29 | Imclone Systems Incorporated | Human anti-epidermal growth factor receptor antibody |
| PL1730191T3 (pl) | 2004-03-30 | 2011-12-30 | Glaxo Group Ltd | Immunoglobuliny wiążące hosm |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| WO2006078307A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| AU2006214105A1 (en) | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| US7510842B2 (en) | 2005-03-11 | 2009-03-31 | Vermilllion, Inc. | Biomarker for ovarian and endometrial cancer: hepcidin |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| EP1991701A4 (en) | 2006-02-14 | 2010-03-17 | Dana Farber Cancer Inst Inc | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER |
| US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| JP2010023451A (ja) | 2008-07-24 | 2010-02-04 | Konica Minolta Business Technologies Inc | 画像形成装置、画像形成方法および画像形成プログラム |
| RU2498819C2 (ru) * | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| KR101669827B1 (ko) | 2008-08-05 | 2016-10-27 | 도레이 카부시키가이샤 | 면역 유도제 |
| DK2733492T3 (en) | 2008-08-05 | 2016-04-25 | Toray Industries | Method for detection of cancer |
| EA032728B1 (ru) | 2009-08-19 | 2019-07-31 | Мерк Патент Гмбх | Антитела для выявления комплексов интегрина в ffpe материале |
| MX2012003404A (es) | 2009-09-22 | 2012-09-12 | Volker Sandig | Procedimiento para producir moleculas que contienen estructuras de glicano especializadas. |
| US9984787B2 (en) | 2009-11-11 | 2018-05-29 | Samsung Electronics Co., Ltd. | Conductive paste and solar cell |
| DK2532365T3 (en) | 2010-02-04 | 2016-08-15 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER |
| HUE030742T2 (en) | 2010-02-04 | 2017-06-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| BR112012018949A2 (pt) | 2010-02-04 | 2020-09-01 | Toray Industries | Composições farmacêuticas, anticorpos, combinação farmacêutica, métodos para o tratamento e/ou prevenção de um câncer, usos de uma composição farmacêutica, uso5 de um anticorpo e uso de uma combinação farmacêutica |
| RU2624029C2 (ru) | 2010-02-04 | 2017-06-30 | Торэй Индастриз, Инк. | Лекарственный препарат для лечения и/или профилактики рака |
| RU2567657C2 (ru) | 2010-02-04 | 2015-11-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| DK2532364T3 (en) | 2010-02-04 | 2016-08-15 | Toray Industries | PHARMACEUTICAL COMPOSITION CONTAINING ANTI CAPRIN-1 ANTIBODIES FOR TREATMENT AND / OR PREVENTION OF CANCER |
| BR112014002616B1 (pt) | 2011-08-04 | 2022-01-18 | Toray Industries, Inc | Método para detectar câncer pancreático |
| ES2609846T3 (es) | 2011-08-04 | 2017-04-24 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o prevención del cáncer pancreático |
| ES2634249T3 (es) | 2011-08-04 | 2017-09-27 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
| CA2869120C (en) | 2012-03-30 | 2023-05-23 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
-
2011
- 2011-02-04 DK DK11739876.8T patent/DK2532365T3/en active
- 2011-02-04 US US13/576,969 patent/US9115200B2/en active Active
- 2011-02-04 MX MX2012008999A patent/MX340014B/es active IP Right Grant
- 2011-02-04 HU HUE11739876A patent/HUE030103T2/en unknown
- 2011-02-04 KR KR1020127022734A patent/KR101842893B1/ko active IP Right Grant
- 2011-02-04 WO PCT/JP2011/052403 patent/WO2011096528A1/ja active Application Filing
- 2011-02-04 BR BR112012018947A patent/BR112012018947B8/pt active IP Right Grant
- 2011-02-04 CN CN201180017346.7A patent/CN102821788B/zh active Active
- 2011-02-04 ES ES11739876.8T patent/ES2583627T3/es active Active
- 2011-02-04 CA CA2788715A patent/CA2788715C/en active Active
- 2011-02-04 RU RU2012137498A patent/RU2607366C2/ru active
- 2011-02-04 EP EP11739876.8A patent/EP2532365B1/en active Active
- 2011-02-04 PT PT117398768T patent/PT2532365T/pt unknown
- 2011-02-04 PL PL11739876.8T patent/PL2532365T3/pl unknown
- 2011-02-04 JP JP2011510207A patent/JP5742714B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2788715C (en) | 2021-06-08 |
| AU2011211693A1 (en) | 2012-08-23 |
| MX2012008999A (es) | 2012-08-31 |
| RU2012137498A (ru) | 2014-03-10 |
| US9115200B2 (en) | 2015-08-25 |
| PT2532365T (pt) | 2016-07-28 |
| BR112012018947A8 (pt) | 2017-12-19 |
| PL2532365T3 (pl) | 2016-12-30 |
| EP2532365A1 (en) | 2012-12-12 |
| US20120301476A1 (en) | 2012-11-29 |
| JPWO2011096528A1 (ja) | 2013-06-13 |
| DK2532365T3 (en) | 2016-08-15 |
| BR112012018947B1 (pt) | 2020-04-28 |
| JP5742714B2 (ja) | 2015-07-01 |
| EP2532365B1 (en) | 2016-05-04 |
| ES2583627T3 (es) | 2016-09-21 |
| KR101842893B1 (ko) | 2018-03-28 |
| MX340014B (es) | 2016-06-22 |
| CN102821788A (zh) | 2012-12-12 |
| HUE030103T2 (en) | 2017-04-28 |
| EP2532365A4 (en) | 2013-12-04 |
| CA2788715A1 (en) | 2011-08-11 |
| WO2011096528A1 (ja) | 2011-08-11 |
| RU2607366C2 (ru) | 2017-01-10 |
| KR20120123500A (ko) | 2012-11-08 |
| BR112012018947A2 (pt) | 2017-06-27 |
| CN102821788B (zh) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012018947B8 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| BR112012018951A8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| BR112012019098B8 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica | |
| MX2014001375A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| BR112016001753A2 (pt) | Anticorpo, anticorpo ou seu fragmento, composição de anticorpo, célula, composição farmacêutica, produto de droga de combinação e método de tratamento e/ou prevenção de câncer | |
| MX360208B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX363136B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| BRPI0821110B8 (pt) | anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo | |
| MX2023010178A (es) | Conjugados de anticuerpo farmaco anti-cd70. | |
| BR112014021251A2 (pt) | anticorpos humanos para toxinas de clostridium difficile | |
| BR112015009037A2 (pt) | composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1 | |
| BR112017019343A2 (pt) | uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas | |
| BR112014027991A2 (pt) | agentes para neutralização de influenza | |
| BR112017010832A2 (pt) | composições de aminoácido para o tratamento de sintomas de doença | |
| BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
| BR112015008745A2 (pt) | método para tratamento de lesão ao cordão espinhal usando fragmento de hmgb1 | |
| BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
| BR112019011350A2 (pt) | terapia de combinação | |
| BR112017022390A2 (pt) | composição farmacêutica | |
| BR112018069332A2 (pt) | composição e combinação farmacêutica para tratamento e/ou prevenção do câncer, anticorpo ou fragmento do mesmo e método para tratar e/ou prevenir um câncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/02/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant |
Free format text: REF. RPI 2573 DE 28/04/2020 QUANTO AO ENDERECO. |